4574 — Taiko Pharmaceutical Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 17.01 | ||
| PEG Ratio (f) | 1.87 | ||
| EPS Growth (f) | 10.01% | ||
| Dividend Yield (f) | 1.43% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.56 | ||
| Price to Tang. Book | 1.57 | ||
| Price to Free Cashflow | 37.73 | ||
| Price to Sales | 1.98 | ||
| EV to EBITDA | 14.53 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 4.19% | ||
| Return on Equity | 8.4% | ||
| Operating Margin | 6.13% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 11,299 | 5,040 | 6,120 | 6,292 | 6,397 | 7,300 | 8,015 | -15.63% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | -5.66 | -30.3 | +23.26 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
TAIKO PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company. The Company is engaged in three business segments. The Pharmaceutical Product segment is engaged in the manufacturing, sales and export of gastrointestinal drugs under the name SEIROGAN, SEIROGAN TOI-A (sugar coated tablet) and PISHUT. The Infection Control segment is engaged in the planning, development and sales of infection control products, which apply proprietary technique regarding chlorine dioxide gas. The Others segment is engaged in the manufacturing and sales of bath liquid, soap and gardening pyroligneous acid.
Directors
- Hitoshi Shibata CHM (67)
- Takashi Shibata PRE (57)
- Tomosada Yoshikawa SMD (53)
- Atsunori Kato EDR (57)
- Masami Moroi EDR (62)
- Masashi Terakami EDR (60)
- Takaaki Higashino OTH (48)
- Hideo Inagaki DRC (62)
- Motoo Matsuzawa DRC
- Kazuo Nakazawa IND
- Koki Yanagisawa IND
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- November 18th, 1946
- Public Since
- March 18th, 2009
- No. of Shareholders
- 14,853
- No. of Employees
- 220
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Tokyo Stock Exchange
- Shares in Issue
- 50,308,081
- Address
- 16F, ORIX Hommachi Bldg.,, OSAKA-SHI, 550-0005
- Web
- https://www.seirogan.co.jp/
- Phone
- +81 643911110
- Auditors
- KPMG AZSA LLC
Latest News for 4574
Upcoming Events for 4574
Q3 2026 Taiko Pharmaceutical Co Ltd Earnings Release
Dividend For 4574.T - 3.5000 JPY
Similar to 4574
ASKA Pharmaceutical Holdings
Tokyo Stock Exchange
Astellas Pharma
Tokyo Stock Exchange
Astena Holdings
Tokyo Stock Exchange
CanBas
Tokyo Stock Exchange
CellSeed
Tokyo Stock Exchange
FAQ
As of Today at 23:36 UTC, shares in Taiko Pharmaceutical are trading at ¥261. This share price information is delayed by 15 minutes.
Shares in Taiko Pharmaceutical last closed at ¥261 and the price had moved by -13% over the past 365 days. In terms of relative price strength the Taiko Pharmaceutical share price has underperformed the Nikkei 225 Index by -32.5% over the past year.
The overall consensus recommendation for Taiko Pharmaceutical is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Taiko Pharmaceutical dividend yield is 1.26% based on the trailing twelve month period.
Last year, Taiko Pharmaceutical paid a total dividend of ¥3, and it currently has a trailing dividend yield of 1.26%.Looking ahead, shares in Taiko Pharmaceutical are due to go ex-dividend on 2026-12-29 and the next dividend pay date is 2027-03-30.
Taiko Pharmaceutical are due to go ex-dividend on 2026-12-29 and the next dividend pay date is 2027-03-30. The historic dividend yield on Taiko Pharmaceutical shares is currently 1.26%.
To buy shares in Taiko Pharmaceutical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of ¥261, shares in Taiko Pharmaceutical had a market capitalisation of ¥13bn.
Here are the trading details for Taiko Pharmaceutical:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 4574
Based on an overall assessment of its quality, value and momentum Taiko Pharmaceutical is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Taiko Pharmaceutical is ¥3,300. That is 1164.37% above the last closing price of ¥261.
Analysts covering Taiko Pharmaceutical currently have a consensus Earnings Per Share (EPS) forecast of ¥13 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Taiko Pharmaceutical. Over the past six months, its share price has underperformed the Nikkei 225 Index by -13.98%.
As of the last closing price of ¥261, shares in Taiko Pharmaceutical were trading -5.69% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Taiko Pharmaceutical PE ratio based on its reported earnings over the past 12 months is 17.01. The shares last closed at ¥261.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Taiko Pharmaceutical's management team is headed by:
- Hitoshi Shibata - CHM
- Takashi Shibata - PRE
- Tomosada Yoshikawa - SMD
- Atsunori Kato - EDR
- Masami Moroi - EDR
- Masashi Terakami - EDR
- Takaaki Higashino - OTH
- Hideo Inagaki - DRC
- Motoo Matsuzawa - DRC
- Kazuo Nakazawa - IND
- Koki Yanagisawa - IND